RxDoctor Payments Data

William Arce Montoya, MD

Family Medicine · Hollywood, FLNPI 1497078828

Payments from drug & device makers

$422in general payments, 2019–2025

Across 16 payments — averaging $26.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$134
  • AstraZeneca$117
  • Novo Nordisk$53
  • Exact Sciences$27
  • Boehringer Ingelheim$25
  • Genentech USA, Inc.$23
  • plus $43 from 2 others

What the payments were for

  • Food & beverage$422100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$422 in reported general payments places this provider in the 45th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$3,663
Medicare patients
11
Services billed
54

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin190$207,438
RybelsusSemaglutide66$129,665
XareltoRivaroxaban47$52,078
FarxigaDapagliflozin Propanediol31$44,836
OzempicSemaglutide36$42,134
EliquisApixaban28$42,132
LinzessLinaclotide32$36,044
JanuviaSitagliptin Phosphate16$21,774
VascepaIcosapent Ethyl30$20,141
RestasisCyclosporine19$14,331
TrulicityDulaglutide13$13,373
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$12,141
MyrbetriqMirabegron18$9,882
GemtesaVibegron13$6,486
Diclofenac Sodium52$5,181

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$25$207,438190 claims
Novo NordiskRybelsus, Ozempic$53$171,799102 claims
AstraZenecaFarxiga, Symbicort$117$47,85644 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Hollywood

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →